Emergent Management of Lactic Acidosis 

  • Author: Bret A Nicks, MD, MHA; Chief Editor: Rick Kulkarni, MD   more...
 
Updated: May 24, 2011
 

Overview

Metabolic acidosis is defined as a state of decreased systemic pH resulting from either a primary increase in hydrogen ion (H+) or a reduction in bicarbonate (HCO3-) concentrations. In the acute state, respiratory compensation of acidosis occurs by hyperventilation resulting in a relative reduction in PaCO2. Chronically, renal compensation occurs by means of reabsorption of HCO3.[1]

Acidosis arises from an increased production of acids, a loss of alkali, or a decreased renal excretion of acids. The underlying etiology of metabolic acidosis is classically categorized into those that cause an elevated anion gap (AG) and those that do not. Lactic acidosis, identified by a state of acidosis and an elevated plasma lactate concentration is one type of anion gap metabolic acidosis and may result from numerous conditions.[2]

The normal blood lactate concentration in unstressed patients is 1-0.5 mmol/L. Patients with critical illness can be considered to have normal lactate concentrations of less than 2 mmol/L. Hyperlactatemia is defined as a mild to moderate persistent increase in blood lactate concentration (2-5 mmol/L) without metabolic acidosis, whereas lactic acidosis is characterized by persistently increased blood lactate levels (usually >4-5 mmol/L) in association with metabolic acidosis.[1, 3]

Elevated lactate levels as a marker for inadequate tissue perfusion should be considered within the confines of each patient individually, because it alone cannot provide definitive confirmation of disease presence, severity, or prognosis.

See also the following:

Next

Treatment Overview

As mentioned earlier, lactic acidosis is characterized by an excess of serum lactate due to lactate production that exceeds systemic consumption. Numerous etiologies may be responsible for its presence, most commonly circulatory failure and hypoxia. Evidence suggests increased morbidity and mortality for patients with persistently elevated or increasing lactate levels.

In addition to general supportive measures, identification and discontinuation of any offending agents and treatment of known pathology should occur promptly. Treatment may include the administration of appropriate antibiotics, surgical drainage or debridement, chemotherapy for malignancy, discontinuation of potentially causative medications, and dietary modification in inborn errors of metabolism.

Although treatment with buffering agents remains controversial, their use should be considered in certain instances with the assistance of appropriate medical consultation. In addition, there is a growing body of literature showing the benefit of acute medical management, appropriate intervention (including early goal directed therapy) and lactate clearance.

Aside from resuscitation measures including adequate intravenous access and airway stabilization in all potentially ill patients, hemoperfusion or hemodialysis may be indicated in association with ethylene glycol and methanol poisoning. Dialysis may also be useful when severe lactic acidosis exists in the setting of renal failure or congestive heart failure and additionally with metformin intoxication.

Previous
Next

Prehospital Care

Initial treatment of lactic acidosis predicates an understanding of basic resuscitation. Airway assessment and stabilization is essential for all patients. Supplemental oxygen may be required, and the airway must be repeatedly reassessed, especially if the patient's mental status or vital signs decline.

An intravenous (IV) line should be established, and fluid repletion with normal saline may be initiated if the patient exhibits tachycardia, hypotension, or other signs of poor tissue perfusion (eg, poor capillary refill, cool extremities). Vital signs and cardiac rhythm must be monitored closely, because acidosis predisposes to dysrhythmias including tachydysrhythmias and fibrillation.

Established prehospital treatment protocols should be followed, and nonprotocol medications, such as sodium bicarbonate, should be administered only in conjunction with medical control. Transport all patients to the appropriate emergency facility for further management.

Previous
Next

Emergency Department Care

Lactic acidosis is typically associated with tissue hypoperfusion and states of acute circulatory failure. Treatment of lactic acidosis requires identification of the primary illness and appropriately directed therapy.

Restoration of tissue oxygen delivery, thereby causing cessation of acid production, remains the primary therapeutic focus. Early goal-directed therapy for sepsis is well described and is associated with improved outcomes. Appropriate measures include treatment of shock, restoration of circulating fluid volume, improved cardiac function, identification of sepsis source and appropriate therapy, and resection of any potential ischemic regions.[4, 5]

Previous
Next

Pharmacotherapy

One of the primary goals in treating critically ill patients is maximizing systemic oxygen delivery. Much debate has surrounded the potential use of buffering agents (specifically bicarbonate) to reverse the potentially negative effects of acidosis, but their use is generally advocated in the setting of severe acidosis. It has also been demonstrated that bicarbonate therapy alone does not improve hemodynamics in the critically ill patient with lactic acidosis, and this treatment may induce a paradoxical worsening acidosis in brain tissues.[6, 7]

It seems somewhat intuitive that acidosis should be corrected and homeostasis maintained for physiologic functions to return. However, large studies have been conducted that do not necessarily support this approach. Before the initiation of pharmacologic buffering therapy, consultation with a critical care specialist and/or nephrologist should be considered to determine the optimal course of action.

Sodium bicarbonate

The starting dose of sodium bicarbonate (NaHCO3-) is one third to one half of the calculated extracellular bicarbonate (HCO3-) deficit, as illustrated by the following formula:

HCO3 deficit (in mEq) = 0.5 × (Wt in kg) × (Desired HCO3 – Measured HCO3)

Metabolic alkalosis can ensue after bicarbonate administration if the correction is complete rather than partial. This result can be avoided by titration of the bicarbonate dose to modest therapeutic end points (eg, arterial pH of 7.20). In severe hypoxemia, sodium bicarbonate should be administered by slow infusion to minimize any increase in central venous carbon dioxide tension (PvCO2). Minute ventilation must be increased in order to expel carbon dioxide (CO2) generated by bicarbonate administration. Because of increased CO2 production, sodium bicarbonate may precipitate ventilatory failure and, as such, must be given with caution.

Toxic etiologies of lactic acidosis, such as methanol, ethylene glycol, and cyanide poisoning, may justify administration of bicarbonate (See Cyanide Toxicity, Ethylene Glycol Toxicity, and Toxicity, Alcohols). These are unique circumstances that require bicarbonate therapy to facilitate the detoxification processes.

Thiamine

Thiamine deficiency may be associated with cardiovascular compromise and lactic acidosis. The response to thiamine repletion (given as 50-100 mg intravenously [IV] followed by 50 mg/d orally [PO] for 1-2 wk) may be dramatic and potentially lifesaving.

Other agents

The following agents have theoretical advantages but either have not been proven to be more effective than bicarbonate or have not been demonstrated to be effective in humans.

Tris-[hydroxymethyl] aminomethane

Tris-[hydroxymethyl] aminomethane (THAM) has theoretical advantages over bicarbonate because CO2 is not generated. This agent has been studied in animals and humans but has not been proven to be more effective than bicarbonate.

Carbicarb

Carbicarb is a combination of sodium carbonate and sodium bicarbonate that buffers comparably to bicarbonate but does not generate CO2. Although this theoretical advantage should favor its use over bicarbonate, there is no evidence in humans to support improved outcomes.

Dichloroacetate

Dichloroacetate is not a buffer, but this agent stimulates the oxidation of pyruvate. This has resulted in improved lactate utilization and increased tissue levels of adenosine-triphosphate (ATP). However, prospective studies have failed to demonstrate its efficacy.

Miscellaneous agents

Coenzyme Q, l-carnitine, and riboflavin have been used to treat lactic acidosis due to antiretroviral therapy, without definitive demonstration of efficacy.

Previous
Next

Outcomes

Lactate levels have been well described to correlate with the presence of tissue hypoperfusion in shock. Elevated levels have been shown to be correlated with increased mortality. Serum lactate levels above 4 mmol/L were associated with a survival of only 11% in critically ill patients in the intensive care unit (ICU) if persistent after 24 hours. Further studies have demonstrated an association between a 12-hour rise in lactate concentration above 2.5 mmol/L and multisystem organ failure.[3, 4, 8]

The duration and degree of increased serum lactic acid appear to predict morbidity and mortality. Abramson et al identified 100% survival with normalization of serum lactate concentration (< 2 mmol/L) within the first 24 hours following multiple trauma, 78% survival if normalization occurred in 24-48 hours, and only 14% survival if after 48 hours.[9]

With the onset of bedside serum lactate analyzers, measurements can be obtained in minutes with excellent correlation with traditional measurements. Studies have been performed to predict required hospital admission and mortality, but they were unable to define a lactate level below which a patient could be safely discharged from the emergency department. The lactate level should be used only as a single tool in combination with clinical findings and other measures of circulatory failure rather than as a decisive indicator of disease severity. It provides unique information related to improving perfusion and resuscitation, but this must be taken in context of the clinical scenario.

Previous
 
Contributor Information and Disclosures
Author

Bret A Nicks, MD, MHA  Assistant Dean of Global Health, Assistant Professor, Medical Director, ED Clinical Operations, Department of Emergency Medicine, Wake Forest University School of Medicine

Bret A Nicks, MD, MHA is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, Christian Medical & Dental Society, Society for Academic Emergency Medicine, and Wilderness Medical Society

Disclosure: Nothing to disclose.

Coauthor(s)

Henderson D McGinnis, MD  Assistant Medical Director, AirCare Critical Care Transport Services; Clinical Instructor, Department of Emergency Medicine, Wake Forest University Baptist Medical Center

Disclosure: Nothing to disclose.

Stephen W Borron, MD, MS, FACEP, FACMT  Professor of Emergency Medicine and Medical Toxicology, Division of Medical Toxicology, Department of Emergency Medicine, Paul L Foster School of Medicine, Texas Tech University Health Sciences Center; Associate Medical Director, West Texas Regional Poison Center

Stephen W Borron, MD, MS, FACEP, FACMT is a member of the following medical societies: American Academy of Clinical Toxicology, American College of Emergency Physicians, American College of Medical Toxicology, American College of Occupational and Environmental Medicine, American Industrial Hygiene Association, and European Association of Poisons Centres and Clinical Toxicologists

Disclosure: Meridian Pharmaceuticals Consulting fee Consulting

Bruno Mégarbane, MD  Fellow, Medical and Toxicological Intensive Care Unit, Lariboisière University Hospital, France

Disclosure: Nothing to disclose.

Specialty Editor Board

Erik D Schraga, MD  Staff Physician, Department of Emergency Medicine, Mills-Peninsula Emergency Medical Associates

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: eMedicine Salary Employment

Howard A Bessen, MD  Professor of Medicine, Department of Emergency Medicine, University of California, Los Angeles, David Geffen School of Medicine; Program Director, Harbor-UCLA Medical Center

Howard A Bessen, MD is a member of the following medical societies: American College of Emergency Physicians

Disclosure: Nothing to disclose.

Chief Editor

Rick Kulkarni, MD 

Rick Kulkarni, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Emergency Medicine, American College of Emergency Physicians, American Medical Association, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine

Disclosure: WebMD Salary Employment

References
  1. Cohen R, Woods H. Clinical and Biochemical Aspects of Lactic Acidosis. London, United Kingdom: Blackwell Scientific Publications; 1976.

  2. Forrest DM, Russell JA. Metabolic acidosis. In: Webb A, Shapiro M, Singer M, Suter P, eds. Oxford Textbook of Critical Care. Oxford, United Kingdom: Oxford University Press; 1999:573-7.

  3. Mizock BA, Falk JL. Lactic acidosis in critical illness. Crit Care Med. Jan 1992;20(1):80-93. [Medline].

  4. Jones AE, Shapiro NI, Trzeciak S, Arnold RC, Claremont HA, Kline JA. Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy: a randomized clinical trial. JAMA. Feb 24 2010;303(8):739-46. [Medline].

  5. Lima A, van Bommel J, Jansen TC, Ince C, Bakker J. Low tissue oxygen saturation at the end of early goal-directed therapy is associated with worse outcome in critically ill patients. Crit Care. 2009;13 Suppl 5:S13. [Medline].

  6. Cooper DJ, Walley KR, Wiggs BR, Russell JA. Bicarbonate does not improve hemodynamics in critically ill patients who have lactic acidosis. A prospective, controlled clinical study. Ann Intern Med. Apr 1 1990;112(7):492-8. [Medline].

  7. Forsythe SM, Schmidt GA. Sodium bicarbonate for the treatment of lactic acidosis. Chest. Jan 2000;117(1):260-7. [Medline].

  8. Kamolz LP, Andel H, Schramm W, Meissl G, Herndon DN, Frey M. Lactate: early predictor of morbidity and mortality in patients with severe burns. Burns. Dec 2005;31(8):986-90. [Medline].

  9. Abramson D, Scalea TM, Hitchcock R, Trooskin SZ, Henry SM, Greenspan J. Lactate clearance and survival following injury. J Trauma. Oct 1993;35(4):584-8; discussion 588-9. [Medline].

Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.